UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 207,456 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 766.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 234,537 shares of the company's stock after buying an additional 207,456 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.24% of ARS Pharmaceuticals worth $3,401,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. nVerses Capital LLC bought a new position in ARS Pharmaceuticals during the third quarter valued at about $30,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of ARS Pharmaceuticals by 151.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company's stock valued at $63,000 after acquiring an additional 4,472 shares during the last quarter. Principal Financial Group Inc. bought a new position in shares of ARS Pharmaceuticals in the 2nd quarter valued at approximately $87,000. J.W. Cole Advisors Inc. lifted its holdings in ARS Pharmaceuticals by 10.8% in the 2nd quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company's stock worth $131,000 after purchasing an additional 1,500 shares during the last quarter. Finally, The Manufacturers Life Insurance Company bought a new stake in ARS Pharmaceuticals during the second quarter worth approximately $180,000. Institutional investors and hedge funds own 68.16% of the company's stock.

Wall Street Analyst Weigh In

SPRY has been the topic of a number of recent analyst reports. William Blair raised shares of ARS Pharmaceuticals to a "strong-buy" rating in a research report on Friday, August 30th. Leerink Partners lifted their target price on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an "outperform" rating in a report on Friday, September 20th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $30.00 price target on shares of ARS Pharmaceuticals in a report on Tuesday, October 8th. Four investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $24.00.

ARS Pharmaceuticals Price Performance

Shares of ARS Pharmaceuticals stock traded down $0.74 during midday trading on Friday, hitting $11.90. The company had a trading volume of 984,940 shares, compared to its average volume of 825,045. ARS Pharmaceuticals, Inc. has a 1-year low of $5.02 and a 1-year high of $18.51. The business's 50 day simple moving average is $14.62 and its two-hundred day simple moving average is $12.37. The stock has a market cap of $1.16 billion, a PE ratio of -23.33 and a beta of 0.88.

Insider Buying and Selling at ARS Pharmaceuticals

In other news, major shareholder James E. Flynn sold 528,456 shares of the business's stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $18.04, for a total transaction of $9,533,346.24. Following the sale, the insider now directly owns 5,274,735 shares in the company, valued at approximately $95,156,219.40. The trade was a 9.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Brian Dorsey sold 25,000 shares of the company's stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $12.30, for a total value of $307,500.00. Following the completion of the transaction, the chief operating officer now owns 6,024 shares of the company's stock, valued at $74,095.20. The trade was a 80.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,268,058 shares of company stock valued at $19,635,686 in the last ninety days. Company insiders own 40.10% of the company's stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.